Better tracking of patient-reported outcomes, not just weight loss
Pros and Cons Ro Pros Predictable pricing
Back Zander, M, Madsbad, S, Madsen, JL, Holst, JJ (9 March 2002) 'Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study', The Lancet , 359/9309, 824-30
Lixisenatide in Patients With Type 2 Diabetes and Acute Coronary Syndrome
But while people who get their GLP-1s through self-pay programs or other kinds of insurance might be able to switch products, the limited products in the Bridge program mean Medicare participants will have fewer options if manufacturers cant keep up
The specific reactions users report most often: Compare this to actual GLP-1 receptor agonists, where nausea affects 20 to 44% of users, vomiting 5 to 24%, and constipation 12 to 24% across the STEP 1 and SURMOUNT-1 trial programs